Matoussevitch Vladimir, Dorweiler Bernhard, Kalmykov Egan
Department of Vascular and Endovascular Surgery, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
Brandenburg Medical School Theodor Fontane, Department of Vascular and Endovascular Surgery, Brandenburg University Clinic, Brandenburg, Germany.
Vascular. 2025 Aug;33(4):879-885. doi: 10.1177/17085381241259645. Epub 2024 Jun 12.
ObjectiveThe HeRO graft is a technique for vascular access in patients with limited treatment options; however, the published results with the HeRO graft are diverging. We therefore conducted a single-center study.MethodsPatient records between July 2014 and February 2020 from Vascular Access Unit of the Department of Vascular and Endovascular Surgery of University Clinic of Cologne (Germany) were reviewed. Retrospective data was analysed from patients with a HeRo graft ( = 18).ResultsEighteen patients were enrolled in the study. The mean age of the patients was 62.8 ± 17.24 years. During the follow-up period, no patients died from complications related to the HeRO graft. Each patient had a mean of 1.94 concomitant diseases. The primary patency rates of the HeRO graft at 3, 6, 12, 18, and 24 months were 61.1%, 50%, 16.7%, 11.1%, and 5.6%, respectively. The secondary patency rates at the same time intervals were 77.8%, 72.8%, 55.6% 55.6%, and 55.6%, respectively. There were 44 re-operations per year, or 2.4 operations per patient. The main cause of acute complications was acute graft occlusions after HERO graft implantation. An infection after the graft implantation occurred in five (27.7%) patients, leading to graft explanation in 2 cases.ConclusionThe use of the HERO graft is a valuable alternative method for providing a durable dialysis access in patients with limited access options. The secondary patency and survival are good with a low infection rate.
目的
HeRO移植物是一种用于治疗选择有限的患者的血管通路技术；然而，关于HeRO移植物已发表的结果存在分歧。因此，我们进行了一项单中心研究。
方法
回顾了2014年7月至2020年2月德国科隆大学医院血管与血管内外科血管通路科的患者记录。对18例接受HeRo移植物的患者进行了回顾性数据分析。
结果
18例患者纳入研究。患者的平均年龄为62.8±17.24岁。在随访期间，没有患者死于与HeRO移植物相关的并发症。每位患者平均有1.94种合并症。HeRO移植物在3、6、12、18和24个月时的初级通畅率分别为61.1%、50%、16.7%、11.1%和5.6%。在相同时间间隔的次级通畅率分别为77.8%、72.8%、55.6%、55.6%和55.6%。每年有44次再次手术，即每位患者2.4次手术。急性并发症的主要原因是HERO移植物植入后急性移植物闭塞。5例（27.7%）患者在移植物植入后发生感染，其中2例导致移植物取出。
结论
对于血管通路选择有限的患者，使用HERO移植物是一种提供持久透析通路的有价值的替代方法。次级通畅率和生存率良好，感染率低。
